BioSpace News Archive

Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced financial results for the first quarter of 2022.

Pipeline Therapeutics announced that company management will present at the following investor conferences.

BELLUS Health Inc. reported its financial and operating results for the first quarter ending March 31, 2022.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on May 9, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 14,500 shares of Puma common stock to three new non-executive employees.

Shanghai Zhimeng Biopharma, Inc., announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule KCNQ2/3 selective opener, developed for the treatment of refractory epilepsy.

CANbridge Pharmaceuticals, Inc. announced that it has appointed Pauline Li, MD, to the position of Senior Vice President of Clinical Development and Operations, effective as of May 8.

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on its corporate activities and product pipeline.

Thorne HealthTech, Inc. (“Thorne HealthTech” or “Thorne”) (NASDAQ: THRN), shared the results of a large-scale surveillance study conducted by the Medical Research Council (MRC) Epidemiology Unit, University of Cambridge, to assess the prevalence of previous infection with COVID-19 using remote blood samples collected with the novel patient-administered OneDraw™ Blood Collection Device.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today provided business and program updates, and reported financial results for the first quarter ended March 31, 2022.

The industry analysis report is considered a valuable source of information about the global Automated Immunoassay Analyzers industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.